Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorzoxazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 1.00 |
| ▸ | NOS3 | P29474 | 3/20 | 1.00 |
| ▸ | NOS2 | P35228 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.61 |
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | OGT | O15294 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorzoxazone SCHEMBL29720120 | 1.00 | NOS1 (1.00) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL1519891 | 0.84 | NOS1 (0.72) | NOS1NOS3NOS2LMNACYP1A2 | |
| Chlorzoxazone SCHEMBL8682010 | 0.82 | NOS3 (0.68) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL4261971 | 0.81 | NOS3 (0.68) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL8871997 | 0.81 | CYP1A2 (0.68) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL14920284 | 0.80 | NOS3 (0.65) | NOS1NOS3NOS2LMNACYP1A2 | |
| Chlorzoxazone SCHEMBL3004760 | 0.77 | NOS1 (0.59) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL30557808 | 0.77 | LMNA (0.62) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL30594168 | 0.77 | TSHR (0.62) | NOS1NOS3NOS2LMNACYP1A2 | |
| SCHEMBL625761 | 0.77 | LMNA (0.62) | NOS1NOS3NOS2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9375 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080731-A | Weather-resistant high-hardness composite anticorrosive paint and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12588828-B2 | Methods and systems for diagnosing and treating fibromyalgia | KATZ ROBERT S (US) | 2026-03-31 | — | — | US | claimed |
| EP-4695613-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Yale University (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-4904426-A | MOCROPOROUS; AROMATIC RING-CONTAINING SOLVENT; EXTRUSION, QUENCHING, LEACHING, DRYING | THE DOW CHEMICAL COMPANY (US) | 1990-02-27 | — | — | US | claimed |
| EP-0278785-A2 | Liquid developer compositions with high transfer efficiency | XEROX CORPORATION (US) | 1988-08-17 | — | — | EP | claimed |
| US-4764446-A | Liquid developer compositions with high transfer efficiency | XEROX CORPORATION (US) | 1988-08-16 | — | — | US | claimed |
| EP-0130160-B1 | SMALL PARTICLE FORMATION | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1988-01-07 | — | — | EP | claimed |
| EP-0205492-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE, Abraham (US) | 1986-12-30 | — | — | EP | claimed |
| US-4606939-A | COACERVATION IN SURFACTANTS, WATER SOLUBILITY | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1986-08-19 | — | — | US | claimed |
| WO-1986003681-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE ABRAHAM | 1986-07-03 | — | — | WO | claimed |
| US-4551473-A | Method of inhibiting snoring and obstructive sleep apnea | SCHOSSOW GEORGE W | 1985-11-05 | — | — | US | claimed |
| WO-1985000110-A1 | SMALL PARTICLE FORMATION | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1985-01-17 | — | — | WO | claimed |
| EP-0130160-A2 | Small particle formation | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1985-01-02 | — | — | EP | claimed |